HanAll Biopharma Co., Ltd. – Product Pipeline Review

Global Markets Direct’s, ‘HanAll Biopharma Co., Ltd. – Product Pipeline Review – 2016’, provides an overview of the HanAll Biopharma Co., Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by HanAll Biopharma Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of HanAll Biopharma Co., Ltd.

The report provides overview of HanAll Biopharma Co., Ltd. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses HanAll Biopharma Co., Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features HanAll Biopharma Co., Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate HanAll Biopharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for HanAll Biopharma Co., Ltd.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding HanAll Biopharma Co., Ltd.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

HanAll Biopharma Co., Ltd. Snapshot 6

HanAll Biopharma Co., Ltd. Overview 6

Key Information 6

Key Facts 6

HanAll Biopharma Co., Ltd. - Research and Development Overview 7

Key Therapeutic Areas 7

HanAll Biopharma Co., Ltd. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

HanAll Biopharma Co., Ltd. - Pipeline Products Glance 13

HanAll Biopharma Co., Ltd. - Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13

Phase III Products/Combination Treatment Modalities 14

HanAll Biopharma Co., Ltd. - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

HanAll Biopharma Co., Ltd. - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

HanAll Biopharma Co., Ltd. - Drug Profiles 18

(atorvastatin calcium + losartan potassium) 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

(amlodipine besylate + candesartan cilexetil) 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

(chlorthalidone + telmisartan) 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

cobamamide 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

HL-143 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

(candesartan cilexetil + metformin hydrochloride) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

HL-036 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

somatropin 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

HL-156FIB 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

HL-161 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

HL-176 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

HL-178 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

HL-271 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

HanAll Biopharma Co., Ltd. - Pipeline Analysis 32

HanAll Biopharma Co., Ltd. - Pipeline Products by Target 32

HanAll Biopharma Co., Ltd. - Pipeline Products by Route of Administration 34

HanAll Biopharma Co., Ltd. - Pipeline Products by Molecule Type 35

HanAll Biopharma Co., Ltd. - Pipeline Products by Mechanism of Action 36

HanAll Biopharma Co., Ltd. - Recent Pipeline Updates 38

HanAll Biopharma Co., Ltd. - Dormant Projects 40

HanAll Biopharma Co., Ltd. - Discontinued Pipeline Products 43

Discontinued Pipeline Product Profiles 43

HL-015 43

HL-016 43

Loratadine ODT 43

HanAll Biopharma Co., Ltd. - Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 45

Disclaimer 46

List of Tables

List of Tables

HanAll Biopharma Co., Ltd., Key Information 6

HanAll Biopharma Co., Ltd., Key Facts 6

HanAll Biopharma Co., Ltd. – Pipeline by Indication, 2016 8

HanAll Biopharma Co., Ltd. – Pipeline by Stage of Development, 2016 10

HanAll Biopharma Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

HanAll Biopharma Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 12

HanAll Biopharma Co., Ltd. – Pre-Registration, 2016 13

HanAll Biopharma Co., Ltd. – Phase III, 2016 14

HanAll Biopharma Co., Ltd. – Phase II, 2016 15

HanAll Biopharma Co., Ltd. – Phase I, 2016 16

HanAll Biopharma Co., Ltd. – Preclinical, 2016 17

HanAll Biopharma Co., Ltd. – Pipeline by Target, 2016 32

HanAll Biopharma Co., Ltd. – Pipeline by Route of Administration, 2016 34

HanAll Biopharma Co., Ltd. – Pipeline by Molecule Type, 2016 35

HanAll Biopharma Co., Ltd. – Pipeline Products by Mechanism of Action, 2016 36

HanAll Biopharma Co., Ltd. – Recent Pipeline Updates, 2016 38

HanAll Biopharma Co., Ltd. – Dormant Developmental Projects,2016 40

HanAll Biopharma Co., Ltd. – Discontinued Pipeline Products, 2016 43

HanAll Biopharma Co., Ltd., Other Locations 44

List of Figures

List of Figures

HanAll Biopharma Co., Ltd. – Pipeline by Top 10 Indication, 2016 8

HanAll Biopharma Co., Ltd. – Pipeline by Stage of Development, 2016 10

HanAll Biopharma Co., Ltd. – Monotherapy Products in Pipeline, 2016 11

HanAll Biopharma Co., Ltd. – Combination Treatment Modalities in Pipeline, 2016 12

HanAll Biopharma Co., Ltd. – Pipeline by Top 10 Target, 2016 32

HanAll Biopharma Co., Ltd. – Pipeline by Route of Administration, 2016 34

HanAll Biopharma Co., Ltd. – Pipeline by Molecule Type, 2016 35

HanAll Biopharma Co., Ltd. – Pipeline Products by Top 10 Mechanism of Action, 2016 36

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports